Toxicity testing typically involves studying adverse health outcomes in animals subjected to high doses of toxicants with subsequent extrapolation to expected human responses at lower doses. The system relies on the use of a 40+year-old patchwork of animal tests that are expensive (costing more than $3B per year), time-consuming, low-throughput and often provide results of limited predictive value for human health effects. The low-throughput of current toxicity testing approaches (which are largely the same for industrial chemicals, pesticides and drugs) has led to a backlog of more than 80,000 chemicals to which humans are potentially exposed whose potential toxicity remains largely unknown. In 2007, the National Research Council (NRC) released the report "Toxicity Testing in the 21st Century: A Vision and a Strategy", that charted a long-range strategic plan for transforming toxicity testing. The major components of the plan include the use of predictive, high-throughput cell-based assays (of human origin) to evaluate perturbations in key toxicity pathways, and to conduct targeted testing against those pathways. This approach will greatly accelerate our ability to test the vast "storehouses" of chemical compounds using a rational, risk-based approach to chemical prioritization, and provide test results that are far more predictive of human toxicity than current methods. Although a number of toxicity pathways have already been identified, most are only partially known and no common annotation exists. Mapping the entirety of these pathways (i.e. the Human Toxome) will be a large-scale effort, perhaps on the order of the Human Genome Project. In this project, we propose to comprehensively map pathways of endocrine disruption, representing a first step towards mapping the human toxome. We will leverage our rapidly evolving scientific understanding of how genes, proteins, and small molecules interact to form molecular pathways that maintain cell function, applying orthogonal "omics" approaches (transcriptomics, metabolomics) to map and annotate toxicity pathways for a defined set of endocrine disruptors. Following the identification of toxicity pathways, we will conduct a series of stakeholder workshops to enable development of a consensus-driven process for pathway annotation, validation, sharing and risk assessment, and develop a public database on toxicity pathways, providing a common, community-accessible framework that will enable the toxicology community at large to comprehensively and cooperatively map the human toxome using integrated testing strategies. Finally we will validate the identified pathways of toxicity extend the concepts to additional toxicants, cell systems and endocrine disruptor hazards as well as to additional omics platforms and to dose response modeling.
Toxicity testing typically involves studying adverse health outcomes in animals subjected to high doses of toxicants with subsequent extrapolation to expected human responses at lower doses. The low-throughput of current toxicity testing approaches (which are largely the same for industrial chemicals, pesticides and drugs) has led to a backlog of more than 80,000 chemicals to which humans are potentially exposed whose potential toxicity remains largely unknown. Employing new testing strategies that employ the use of predictive, high-throughput cell-based assays (of human origin) to evaluate perturbations in key toxicity pathways, and to conduct targeted testing against those pathways, we can begin to greatly accelerate our ability to test the vast storehouses of chemical compounds using a rational, risk-based approach to chemical prioritization, and provide test results that are far more predictive of human toxicity than current methods.
|Maertens, Alexandra; Bouhifd, Mounir; Zhao, Liang et al. (2016) Metabolomic network analysis of estrogen-stimulated MCF-7 cells: a comparison of overrepresentation analysis, quantitative enrichment analysis and pathway analysis versus metabolite network analysis. Arch Toxicol :|
|Kleensang, Andre; Vantangoli, Marguerite M; Odwin-DaCosta, Shelly et al. (2016) Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function. Sci Rep 6:28994|
|Yauk, Carole L; Buick, Julie K; Williams, Andrew et al. (2016) Application of the TGx-28.65 transcriptomic biomarker to classify genotoxic and non-genotoxic chemicals in human TK6 cells in the presence of rat liver S9. Environ Mol Mutagen 57:243-60|
|Vantangoli, Marguerite M; Madnick, Samantha J; Wilson, Shelby et al. (2016) Estradiol Exposure Differentially Alters Monolayer versus Microtissue MCF-7 Human Breast Carcinoma Cultures. PLoS One 11:e0157997|
|Vantangoli, Marguerite M; Wilson, Shelby; Madnick, Samantha J et al. (2016) Morphologic effects of estrogen stimulation on 3D MCF-7 microtissues. Toxicol Lett 248:1-8|
|Moffat, Ivy; Chepelev, Nikolai L; Labib, Sarah et al. (2015) Comparison of toxicogenomics and traditional approaches to inform mode of action and points of departure in human health risk assessment of benzo[a]pyrene in drinking water. Crit Rev Toxicol 45:1-43|
|Bouhifd, Mounir; Beger, Richard; Flynn, Thomas et al. (2015) Quality assurance of metabolomics. ALTEX 32:319-26|
|Li, Heng-Hong; Hyduke, Daniel R; Chen, Renxiang et al. (2015) Development of a toxicogenomics signature for genotoxicity using a dose-optimization and informatics strategy in human cells. Environ Mol Mutagen 56:505-19|
|Buick, Julie K; Moffat, Ivy; Williams, Andrew et al. (2015) Integration of metabolic activation with a predictive toxicogenomics signature to classify genotoxic versus nongenotoxic chemicals in human TK6 cells. Environ Mol Mutagen 56:520-34|
|Sauer, John Michael; Hartung, Thomas; Leist, Marcel et al. (2015) Systems Toxicology: The Future of Risk Assessment. Int J Toxicol 34:346-8|
Showing the most recent 10 out of 26 publications